| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
TELA Bio, Inc.$0.85
-0.01 (-1.36%)
F 10Pipeline Score MedTech · Commercial
Market Cap
39.85 M
EPS
-0.80
P/E Ratio
-
Value Trade
123.31 K
SEC Financials
Q1 2026Dilution Risk
Revenue
19.06 M
R&D Expenses
2.34 M
Operating CF
-11.17 M
Total Assets
69.89 M
Total Liabilities
75.09 M
Equity
-5.20 M
D/E Ratio
12,345
-7.31 %
Week
40.62 %
1 Month
16.96 %
3 Month
-18.34 %
6 Month
-93.38 %
5 Year
-93.53 %
All Time
Cash Data
Cash Position
39.54 M
Monthly Burn
3.72 M
Runway
8.9 mo
Burn Trend
SEC Filing
May 13, 2026
Overview
Volume
66.83 K
52 Week Range
0.50 - 2.20
% held by Insiders
26.48 %
% held by Institutions
51.03 %
Enterprise Value
56.70 M
Total Shares
40.31 M
Short %
1.95 %
Float Shares
23.86 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
F10
Pipeline Score -
Pipeline ValueValuation Signal
0
Drugs Scored—
rNPV / MCap Top 8%
Micro Cap (rank 839 of 911)
Percentile RankTELA Bio, Inc. has significant pipeline risk (10/100).
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
OviTex | Ventral Hernia Repair | — | 2020-09-25 | low incidence of surgical site infections and occurrences; none required surgical intervention or implant removal; 85 subjects; 75% met the criteria for Ventral Hernia Working Group (VHWG) grade 2 or grade 3; over 50% of the patients were obese; over one-third had undergone a previous ventral hernia repair; 16% had a history of surgical infections; no patient experienced a hernia recurrence within the first 30-days; no patient experienced a hernia recurrence among the initial 20 patients at two year follow up; five patients experienced an SSO during the two years Read More | TELA Bio Presents Additional Data from BRAVO Study of OviTex for Ventral Hernia Repair MALVERN, PA Read More | |
OviTex | Ventral Hernia Repair | — | 2020-09-25 | low incidence of surgical site infections and occurrences; none required surgical intervention or implant removal; 85 subjects; 75% met the criteria for Ventral Hernia Working Group (VHWG) grade 2 or grade 3; over 50% of the patients were obese; over one-third had undergone a previous ventral hernia repair; 16% had a history of surgical infections; no patient experienced a hernia recurrence within the first 30-days; no patient experienced a hernia recurrence among the initial 20 patients at two year follow up; five patients experienced an SSO during the two years Read More | TELA Bio Presents Additional Data from BRAVO Study of OviTex for Ventral Hernia Repair MALVERN, PA Read More | |
OviTex | Ventral Hernia Repair | — | 2020-09-25 | low incidence of surgical site infections and occurrences; none required surgical intervention or implant removal; 85 subjects; 75% met the criteria for Ventral Hernia Working Group (VHWG) grade 2 or grade 3; over 50% of the patients were obese; over one-third had undergone a previous ventral hernia repair; 16% had a history of surgical infections; no patient experienced a hernia recurrence within the first 30-days; no patient experienced a hernia recurrence among the initial 20 patients at two year follow up; five patients experienced an SSO during the two years Read More | TELA Bio Presents Additional Data from BRAVO Study of OviTex for Ventral Hernia Repair MALVERN, PA Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in TELA
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
TELA Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-07-17 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-07-17 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
TELA▼ -5.9%on this news· ran to -19% by day 3
TELA Bio Reports First Quarter 2026 Financial Results
TELA Bio reported its first quarter 2026 financial results, showing a 3% revenue increase to $19.1 million. The company highlighted strong early productivity from new territory managers and successful international market penetration. However, net losses rose to $12.3 million, and gross margins decreased due to inventory charges. The company reiterated its financial guidance for 2026.
Read more →TELA▲ +11.1%on this news
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
TELA Bio, Inc. has announced the approval of inducement grants covering 89,250 shares of its common stock to 12 newly hired employees. This move is part of the company's strategy to attract talent in alignment with Nasdaq Rule 5635(c)(4). The restricted stock units will vest over four years, encouraging long-term commitment from the employees. TELA Bio focuses on innovative medical technologies for soft-tissue reconstruction.
Read more →TELATELA Bio Announces Strategic Board Refreshment with Four Highly Experienced Commerical Leaders to Accelerate Growth and Drive Path to Profitability; The Company Also Reports Preliminary First Quarter 2026 Revenues
TELA Bio, Inc. has announced a strategic refreshment of its board of directors, with four new members joining to enhance the company's growth and operational capabilities. This change, effective after the 2026 Annual Meeting, aims to support TELA Bio's mission toward sustainable profitability and improved commercial strategies. Additionally, the company reported preliminary revenues of approximately $19.0 million for the first quarter of 2026, slightly exceeding previous guidance. Full financial results will be disclosed on May 12, 2026.
Read more →TELATELA Bio to Announce First Quarter 2026 Financial Results
TELA Bio, Inc. will announce its first quarter 2026 financial results on May 12, 2026. A conference call and webcast will follow at 4:30 p.m. ET to discuss these results and provide a corporate update. Interested investors must register in advance to participate in the call.
Read more →TELA▼ -9.4%on this news· ran to -26% by day 3
TELA Bio Reports Fourth Quarter and Full Year 2025 Financial Results
TELA Bio reported strong financial results for Q4 and full year 2025, with revenues reaching $20.9 million in Q4, an 18% increase from the previous year. The company maintained flat operating expenses while expanding its sales team, which positions it for continued growth. However, it still reported a net loss, highlighting ongoing financial challenges.
Read more →TELATELA Bio to Announce Fourth Quarter and Full Year 2025 Financial Results
TELA Bio, Inc. has announced it will report its fourth quarter and full year 2025 financial results on March 24, 2026. Management will participate in a conference call and webcast to discuss these results and provide a corporate update. The company specializes in innovative solutions for soft-tissue reconstruction while focusing on the preservation of patients' anatomy. Investors interested in the call are required to register in advance.
Read more →TELATELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - January 23, 2026
TELA Bio has announced the approval of inducement grants for five newly-hired employees, totaling 14,250 restricted stock units. These grants, effective January 20, 2026, are part of the company's strategy to enhance its workforce and are tied to the Nasdaq Rule 5635(c)(4). The stock units will vest over four years, contingent on continued employment.
Read more →TELA▼ -8.5%on this news
TELA Bio to Participate in the Piper Sandler 37th Annual Healthcare Conference
TELA Bio, Inc. will participate in the Piper Sandler 37th Annual Healthcare Conference. Scheduled for December 3rd, 2025, at 2:30 pm ET, the event will feature a presentation by TELA's management. Interested parties can access the webcast live or in archive. TELA Bio specializes in soft-tissue reconstruction solutions.
Read more →TELA▼ -10%on this newsshared move
TELA Bio Reports Third Quarter 2025 Financial Results and Refinancing and Upsizing of Credit Facility
TELA Bio reported a 9% increase in revenue for Q3 2025, driven by new customers and international sales. The company also announced a credit facility of up to $70 million to support growth. Despite a net loss of $8.6 million, TELA projects a revenue increase of at least 16% for the full year 2025. Strategic changes in leadership are contributing to improved performance.
Read more →TELATELA Bio Announces Pricing of $13.0 Million Underwritten Registered Direct Offering of Common Stock and Pre-Funded Warrants
TELA Bio, Inc. has announced a registered direct offering of 4,189,000 shares of its common stock, priced at $1.11 per share, and pre-funded warrants for 7,523,000 shares at $1.1099 each. The company expects to raise $13.0 million in gross proceeds, which will be allocated towards general corporate purposes such as sales, marketing, research, and development. The offering, managed by Nantahala Capital and EW Healthcare Partners, is anticipated to close on or about November 17, 2025, pending customary conditions. This move comes under an effective shelf registration statement with the SEC.
Read more →TELA▼ -5.8%on this news
TELA Bio to Announce Third Quarter 2025 Financial Results
TELA Bio, Inc. has announced that it will report its financial results for the third quarter of 2025 on November 13, 2025. Following the report, management will host a conference call and webcast to discuss the results and provide a corporate update. Investors can register to listen to the call in advance.
Read more →TELA▼ -5.8%on this newsshared move
TELA Bio Appoints William Plovanic to Board of Directors
TELA Bio has appointed William Plovanic to its Board of Directors, bringing extensive experience in capital markets and medical technology. Plovanic's background includes leadership roles at Obalon Therapeutics and expertise in corporate strategy. His appointment is expected to enhance TELA's strategy and drive long-term shareholder value.
Read more →TELATELA Bio Announces Addition of Betty Jo Rocchio to Board of Directors and the Departure of Director Lisa Colleran
TELA Bio has appointed Dr. Betty Jo Rocchio to its Board of Directors, succeeding Lisa Colleran, who has stepped down after five years. Dr. Rocchio brings significant healthcare leadership experience and is expected to enhance TELA's strategic direction. The company acknowledges Colleran's contributions to its growth and strategy during her tenure.
Read more →TELA▲ +8.1%on this news
TELA Bio Reports Second Quarter 2025 Financial Results MALVERN, PA
TELA Bio, Inc. reported a 26% increase in its revenue for the second quarter of 2025, totaling $20.2 million, attributed to new customer acquisitions and growing international sales. Despite the positive revenue growth, the company faced challenges with decreasing average selling prices for certain products. Additionally, procedural volumes have normalized following a turbulent previous year marked by cybersecurity issues affecting hospital operations. Leadership changes, including the addition of Jeff Blizard, are expected to further enhance commercial performance.
Read more →TELATELA Bio to Participate in the Canaccord Genuity 45th Annual Growth Conference
TELA Bio, Inc. will participate in the Canaccord Genuity 45th Annual Growth Conference on August 13, 2025. The company's management is scheduled to present at 10:00 am ET, and the event will be accessible via a live and archived webcast. TELA Bio specializes in innovative soft-tissue reconstruction technologies.
Read more →TELA▼ -7%on this newsshared move
TELA Bio to Announce Second Quarter 2025 Financial Results
TELA Bio, Inc. announced it will report its second quarter 2025 financial results on August 11, 2025. Following the release, management will host a conference call and webcast to discuss the financial performance and provide a corporate update. Interested investors must register in advance to participate in the call. TELA Bio is focused on innovative soft-tissue reconstruction solutions and is committed to enhancing surgical outcomes.
Read more →TELATELA Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
TELA Bio, Inc. has announced an inducement grant of stock options and restricted stock units to Jim Hagen, the new Senior Vice President of Strategic Commercial Operations. The grant, which consists of options to purchase 75,000 shares and 30,000 restricted stock units, aims to incentivize Hagen's acceptance of the position and will vest over four years. The stock options have an exercise price of $1.42, equal to the stock’s closing price on the grant date. This move reflects TELA Bio's focus on strategic growth and executive compensation alignments.
Read more →TELA▲ +19.7%on this newsshared move
TELA Bio Announces European Commercial Launch of OviTex® Inguinal for Robotic and Laparoscopic Inguinal Hernia Repair
TELA Bio has announced the European launch of OviTex Inguinal, a reinforced tissue matrix for inguinal hernia repair. This follows a successful U.S. launch where the product generated over $1 million in sales. OviTex Inguinal is designed for laparoscopic and robotic-assisted procedures, offering surgeons tailored options. The product will be showcased at the European Hernia Society Annual Congress in Paris.
Read more →TELATELA Bio Appoints Jeffrey Blizard as President
TELA Bio has appointed Jeffrey Blizard as its new President, effective immediately. Blizard, who has been on TELA's Board of Directors, is expected to leverage his extensive experience in the medical technology field to drive growth and enhance the company's competitive position. His previous roles include significant leadership positions at Abiomed and other leading medtech companies.
Read more →TELATELA Bio Appoints Jeffrey Blizard as President Company Further Strengthens Executive Leadership Team to Drive Next Phase of Growth MALVERN, PA
TELA Bio has appointed Jeffrey Blizard as its new President, effective immediately. Blizard, who has been a board member for the past year, brings extensive experience in the medtech industry, having previously led the Surgical Division at Abiomed. His addition is seen as pivotal for TELA Bio as it embarks on a new growth phase. Company executives express confidence that his leadership will drive commercial performance and strengthen customer relations.
Read more →TELATELA Bio to Participate in the 2025 Jefferies Global Healthcare Conference
TELA Bio, Inc. announced its participation in the upcoming 2025 Jefferies Global Healthcare Conference, scheduled for June 5th, 2025. Company management will present at 11:05 am ET, providing insights into their innovative soft-tissue reconstruction solutions. This participation aims to enhance TELA Bio's visibility in the healthcare sector and attract potential investors and partners. Interested parties can access the webcast live or in an archived format.
Read more →TELATELA Bio Reports First Quarter 2025 Financial Results MALVERN, PA
TELA Bio reported a revenue of $18.5 million for the first quarter of 2025, marking a 12% increase compared to the same period last year. The company launched a larger version of its OviTex PRS product, which is expected to streamline complex surgeries. Despite the positive growth in revenue, TELA Bio faced an increased operating loss and a slight decline in gross profit margin. The company maintains its revenue guidance for the full year, projecting a growth of 23% to 27% over 2024.
Read more →TELATELA Bio to Announce First Quarter 2025 Financial Results
TELA Bio, Inc. announced it will report its first quarter 2025 financial results on May 8, 2025. Management will host a conference call and webcast at 4:30 p.m. ET to discuss the results and provide a corporate update. Investors interested in the call are required to register in advance. TELA Bio specializes in innovative medical technologies for soft-tissue reconstruction, emphasizing patient recovery and minimizing the use of synthetic materials.
Read more →TELATELA Bio Announces U.S. Commercial Launch of Larger Sizes of OviTex PRS for Plastic and Reconstructive Surgery The OviTex PRS portfolio now includes a larger option than any human acellular dermal matrix product on the m
TELA Bio, Inc. has announced the U.S. commercial launch of larger sizes of its OviTex PRS Reinforced Tissue Matrix, a device designed for plastic and reconstructive surgery. The new configurations, including a 25 x 30 cm oval and a 25 cm diameter circle, aim to simplify complex surgical procedures by reducing the need for multiple smaller pieces. The launch comes as part of TELA's commitment to enhance surgical outcomes and meet the evolving demands of surgeons, with notable sales growth since the product's 2019 introduction. The company continues to prioritize innovation in soft-tissue reconstruction solutions.
Read more →TELATELA Bio Reports Fourth Quarter and Full Year
TELA Bio, Inc. reported a 19% revenue growth for the full year 2024, with fourth-quarter revenues reaching $17.6 million, a 4% increase year-over-year. Despite achieving record-high sales months, fourth-quarter results were lower than expected due to various disruptions. The company is optimistic about future growth driven by its innovative soft-tissue reconstruction products, alongside anticipated shifts in surgical market trends. Nevertheless, TELA faces challenges including decreased gross margins and increased operating expenses.
Read more →TELATELA Bio Reports Fourth Quarter and Full Year 2024 Financial Results
TELA Bio, Inc. reported its fourth quarter and full year 2024 financial results, showing a revenue increase of 19% year-over-year, primarily driven by higher unit sales of its OviTex® and OviTex PRS products. The company faced some operational challenges in the fourth quarter that affected overall sales performance. Looking ahead, TELA projects revenue between $85 million and $88 million for 2025, which reflects a positive growth outlook amidst proactive cost management measures. Despite a net loss for the year, the company is optimistic about its potential market benefits and strategic positioning in surgical product alternatives.
Read more →TELATELA Bio to Announce Fourth Quarter and Full Year 2024 Financial Results
TELA Bio, Inc. is set to announce its fourth quarter and full year 2024 financial results on March 20, 2025. The announcement is part of a broader initiative to provide updates regarding the company's financial performance and operational details. Investors can listen to the conference call by registering in advance on the company's website. TELA Bio specializes in innovative technologies for soft-tissue reconstruction, prioritizing patient anatomy preservation.
Read more →TELATELA Bio to Participate in Piper Sandler’s 36th Annual Healthcare Conference
TELA Bio, Inc. has announced its participation in the Piper Sandler’s 36th Annual Healthcare Conference scheduled for December 3rd, 2024. The event will provide TELA's management with a platform to present the company's innovative soft-tissue reconstruction solutions. Interested parties will have access to a live and archived webcast of the presentation. This engagement highlights TELA's focus on optimizing clinical outcomes through advanced medical technology.
Read more →TELATELA Bio Reports Third Quarter 2024 Financial Results Reiterates 2024 Revenue Guidance and Expects Recently Implemented Operational Efficiency Improvements to Reduce Operating Expenses in 2025 MALVERN, PA
TELA Bio reported its third quarter 2024 financial results, achieving record revenues of $19 million, marking a 26% increase year-over-year. The growth was attributed to higher unit sales from new customers and expanding international markets. Although gross profit margins slightly declined due to increased inventory charges, the company is optimistic about achieving profitability with operational efficiency measures and additional funding from a recent public offering. TELA Bio's leadership remains confident in their ability to leverage their growth and overcome current challenges.
Read more →TELATELA Bio Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
TELA Bio, Inc. has announced the successful closing of its public offering of 14,670,000 shares of common stock, raising gross proceeds of $46 million. The offering included a full exercise of the underwriters’ option to purchase additional shares. TELA intends to use the net proceeds for general corporate purposes, including sales, marketing, and R&D activities. The offering was conducted under a previously effective shelf registration statement with the SEC.
Read more →TELA▲ +6.4%on this newsshared move
TELA Bio Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
TELA Bio, Inc. has announced the pricing of a public offering, which includes 12 million shares of common stock offered at $2.25 each, alongside pre-funded warrants for an additional 5.8 million shares. This offering could generate gross proceeds of approximately $40 million before expenses. The funds will be allocated toward general corporate purposes, including sales, marketing, and research activities. The offering is set to close by October 24, 2024, subject to customary conditions.
Read more →TELATELA Bio Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
TELA Bio, Inc. has announced the initiation of an underwritten public offering of common stock and pre-funded warrants. The company plans to use the proceeds for various corporate purposes including sales, marketing, and R&D activities. The offering will be conducted under a previously effective shelf registration statement. However, the offering's completion is subject to market conditions and other uncertainties, which may impact the final terms.
Read more →TELATELA Bio to Announce Third Quarter 2024 Financial Results
TELA Bio, Inc. has announced that it will release its third quarter 2024 financial results on November 7, 2024. The company will also host a conference call and webcast at 4:30 p.m. ET on the same day to discuss the results and provide a corporate update. Investors interested in participating are required to register in advance or at least 15 minutes before the start of the call. TELA aims to offer innovative soft-tissue reconstruction solutions that optimize clinical outcomes.
Read more →TELATELA Bio Reports Second Quarter 2024 Financial Results and Reiterates Full Year 2024 Revenue Guidance MALVERN, PA
TELA Bio, Inc. reported its financial results for the second quarter of 2024, showing a revenue increase of 11% year-over-year to $16.1 million. The company reiterated its revenue guidance for the full year, expecting between $74.5 million to $76.5 million in revenue, projecting a growth of 27% to 31%. However, the company faced disruptions due to cybersecurity incidents that impacted procedure volumes. Despite this, TELA is focusing on enhancing sales productivity under new leadership to achieve profitability.
Read more →TELATELA Bio to Participate in the Canaccord Genuity 44th Annual Growth Conference
TELA Bio, Inc. will participate in the Canaccord Genuity 44th Annual Growth Conference on August 14, 2024. The company's management is scheduled to present at 10:30 am ET, and the presentation can be accessed via a live and archived webcast. TELA Bio focuses on soft-tissue reconstruction solutions that prioritize patient anatomy and minimize the use of synthetic materials. This participation may help the company enhance its visibility and attract potential investors.
Read more →TELATELA Bio to Announce Second Quarter 2024 Financial Results
TELA Bio, Inc. announced that it will report its second quarter 2024 financial results on August 12, 2024. The management will host a conference call and webcast at 4:30 p.m. ET to discuss these results and provide a corporate update. Investors can register online to listen to the call, which will also be available for replay. TELA Bio emphasizes its focus on innovative technologies for soft-tissue reconstruction.
Read more →TELATELA Bio Appoints Jeffrey Blizard to its Board of Directors MALVERN, Pa.
TELA Bio, a medical technology company, has appointed Jeffrey Blizard to its Board of Directors. Blizard, the Global Head of Surgical Sales for Abiomed, is expected to bring significant sales expertise to the company. This move comes as TELA aims to enhance its sales operations during a period of growth. Blizard's previous accomplishments in the medical device sector suggest he will be a valuable addition to TELA's leadership team.
Read more →TELATELA Bio Appoints Greg Firestone as Chief Commercial Officer MALVERN, Pa.
TELA Bio, Inc. has appointed Greg Firestone as the new Chief Commercial Officer. In this role, Firestone will lead commercial operations and implement strategies to enhance market access and reimbursement for TELA's product lines. He has been part of TELA's executive leadership since 2017, significantly contributing to commercial strategy and establishing key partnerships. TELA Bio aims to advance its position in the soft-tissue reconstruction market under Firestone's guidance, addressing unmet needs in healthcare.
Read more →TELATELA Bio Reports First Quarter 2024 Financial Results MALVERN, PA
TELA Bio, Inc. announced its financial results for the first quarter of 2024, reporting a revenue of $16.6 million, a 39% increase from the same period last year. The company has experienced consistent growth with a 13th consecutive quarter of at least 35% year-over-year revenue increase, driven by strong demand for its innovative products. Despite the positive revenue growth, TELA reported a net loss of $5.7 million and increasing operating expenses, raising questions about future profitability. The company has also launched new products and adjusted its revenue guidance for the full year.
Read more →TELATELA Bio to Announce First Quarter 2024 Financial Results
TELA Bio, Inc. will announce its first-quarter 2024 financial results on May 9, 2024, with a conference call scheduled for the same day at 4:30 p.m. ET. The company specializes in soft-tissue reconstruction solutions, emphasizing the preservation of patients' anatomy. Investors can register online for the call, which indicates active communication regarding the company's financial status.
Read more →TELATELA Bio Announces U.S. Commercial Launch of Robotic-Compatible OviTex IHR - Addressing the Need for a More Natural Repair in Inguinal Hernia Procedures Targets the more than 665,000 inguinal hernia procedures performed
TELA Bio, Inc. has announced the U.S. commercial launch of OviTex IHR, a new reinforced tissue matrix designed specifically for inguinal hernia repair. This product offers surgeons multiple configurations compatible with laparoscopic and robotic-assisted procedures, aiming to provide a more natural repair solution. OviTex IHR builds on over eight years of clinical experience, showcasing low recurrence rates and high levels of patient satisfaction. However, the product may not be suitable for patients with sensitivities to sheep-derived materials, which could limit its use.
Read more →TELATELA Bio Welcomes Acclaimed Surgeon as Vice President of Medical Affairs and Surgeon Strategy
TELA Bio, Inc. has announced the appointment of Dr. Howard N. Langstein as Vice President of Medical Affairs and Surgeon Strategy. Dr. Langstein, renowned for his expertise in plastic and reconstructive surgery, aims to leverage his experience to help TELA Bio promote its OviTex® Reinforced Tissue Matrix portfolio. His extensive background includes leadership roles in significant medical institutions which underscores TELA Bio’s commitment to innovative soft-tissue reconstruction solutions.
Read more →TELATELA Bio Achieves Record Fourth Quarter and Full Year 2023 Revenues and Reports Complete Financial Results MALVERN, PA
TELA Bio reported record financial results for the fourth quarter and full year 2023, with revenues of $17.0 million and $58.5 million, respectively, reflecting substantial year-over-year growth. The company launched new products, including LIQUIFIX and OviTex IHR, while also achieving significant sales increases in its existing product lines. However, despite this success, TELA Bio experienced a net loss of $12.9 million in Q4 and a $46.7 million loss for the year. The company has projected a revenue growth of 27% to 30% for the upcoming fiscal year.
Read more →TELATELA Bio Announces U.S. Commercial Launch of LIQUIFIX™ – the Only FDA-Approved Liquid Adhesive for Internal Use in Hernia Surgery
TELA Bio, Inc. has launched the LIQUIFIX devices, the only FDA-approved liquid adhesive for internal hernia surgery in the U.S. These new fixation devices aim to improve surgical outcomes by minimizing tissue trauma compared to traditional methods. Surgeons have reported significant benefits, including reduced post-operative pain. TELA has partnered with Advanced Medical Solutions to leverage their expertise in hernia repair as they target the U.S. market, where there are over 1.2 million hernia procedures annually.
Read more →TELATELA Bio Announces Sale of Distribution Rights for Wound Care Product to MIMEDX TELA Bio to receive at least $8 million and up to $12 million in total consideration. MALVERN, Pa.
TELA Bio, Inc. has announced the sale of its distribution rights for the NIVIS Fibrillar Collagen Pack to MIMEDX Group, Inc. TELA will receive an initial payment of $5 million, with the potential for total consideration ranging between $8 million and $12 million based on net sales. This move allows TELA to leverage MIMEDX’s expertise in the wound care market while focusing on its expanding product portfolio in surgical solutions. The NIVIS product is positioned to aid in the management of wounds, indicating a continued commitment to innovative medical technologies.
Read more →TELATELA Bio to Announce Fourth Quarter and Full Year 2023 Financial Results
TELA Bio, Inc. has announced that it will report its fourth quarter and full year 2023 financial results on March 21, 2024. The management will conduct a conference call and webcast to discuss these results and provide a corporate update. TELA Bio focuses on innovative technologies aimed at optimizing clinical outcomes in soft-tissue reconstruction.
Read more →TELA▼ -6.7%on this news
TELA Bio to Take Part in Connecting the Dots
TELA Bio, Inc. is participating in a new series titled Connecting the Dots, produced by MedTech Europe and BBC StoryWorks. This initiative will feature a mini-documentary highlighting TELA's OviTex Reinforced Tissue Matrix used in hernia repair procedures. The series aims to educate the public about the advancements in hernia treatment options, encouraging awareness of innovative medical technologies. CEO Antony Koblish expressed enthusiasm about the opportunity to showcase their product's role in evolving surgical practices.
Read more →TELATELA Bio to Participate in Piper Sandler’s 35th Annual Healthcare Conference
TELA Bio, Inc. announced its participation in the Piper Sandler’s 35th Annual Healthcare Conference scheduled for November 30, 2023. The company's management will present details about their innovative soft-tissue reconstruction solutions, aimed at improving clinical outcomes. This event represents a significant opportunity for TELA to engage with stakeholders and increase its visibility in the healthcare sector.
Read more →TELATELA Bio Reports Third Quarter 2023 Financial Results MALVERN, PA
TELA Bio, Inc. reported its financial results for the third quarter of 2023, highlighting a revenue increase of 35% year-over-year, marking the 11th consecutive quarter of similar growth. The demand for its OviTex product line has notably increased, contributing to sales figures and positioning OviTex as the top biologic mesh for hernia repairs in the U.S. However, despite strong revenue growth, the company's operating and net losses widened compared to the previous year. TELA Bio has updated its full-year revenue guidance, projecting between $57.0 million and $60.0 million for 2023.
Read more →TELATELA Bio to Announce Third Quarter 2023 Financial Results
TELA Bio, Inc. has announced that it will report its third quarter 2023 financial results on November 9, 2023. Along with the results, the management will host a conference call to discuss the financial outcomes and provide an update on corporate activities. The company is recognized for its focus on soft-tissue reconstruction solutions that optimize clinical outcomes.
Read more →TELATELA Bio to Participate in the Gilmartin Group Emerging Growth Company Showcase
TELA Bio, Inc. will participate in the Gilmartin Group Emerging Growth Company Showcase on September 21st, 2023, at 9:30 am ET. The event showcases emerging companies in medical technology, enhancing TELA's visibility in the industry. The company focuses on innovative soft-tissue reconstruction solutions that prioritize patient anatomy preservation and restoration.
Read more →TELATELA Bio Announces U.S. Commercial Launch of OviTex PRS Long-Term Resorbable for Plastic and Reconstructive Surgery New addition expands reconstruction options for surgeons and patients MALVERN, PA.
TELA Bio, Inc. has announced the U.S. commercial launch of OviTex PRS Long-Term Resorbable, a new addition to its soft-tissue reconstruction product line. The OviTex PRS is designed for use in plastic and reconstructive surgery, providing surgeons with improved options for tissue reinforcement. This product enhances the existing OviTex PRS portfolio and allows for longer-term reinforcement, addressing clinical needs while minimizing the use of permanent materials. The launch is supported by positive feedback from healthcare professionals regarding its design and functionality.
Read more →TELATELA Bio Reports Second Quarter 2023 Financial Results MALVERN, PA
TELA Bio, Inc. reported its second quarter 2023 financial results, showcasing a 39% increase in revenue year-over-year, reaching $14.5 million. The company attributes this growth to a robust sales strategy and improved market conditions for elective procedures. Despite the revenue growth, operating expenses rose to $20.6 million, resulting in a loss from operations of $10.4 million. TELA concluded the quarter with a strong cash reserve of $65.3 million, following a public offering.
Read more →TELATELA Bio to Announce Second Quarter 2023 Financial Results and Confirms Participation in the Canaccord Genuity 43rd Annual Growth Conference
TELA Bio, Inc. is set to announce its second quarter 2023 financial results on August 9, 2023. The company will host a conference call to discuss its results and provide a corporate update. Additionally, TELA Bio will participate in the Canaccord Genuity 43rd Annual Growth Conference on August 10 in Boston, MA, showcasing its commitment to engaging with investors.
Read more →TELATELA Bio to Participate in the Jefferies Global Healthcare Conference
TELA Bio, Inc. announced its participation in the Jefferies Global Healthcare Conference scheduled for June 7th, 2023. The company's management will present at 12:30 pm ET, and the event will be accessible via a live and archived webcast. TELA Bio specializes in soft-tissue reconstruction solutions that emphasize the restoration of the patient's anatomy and are designed to optimize clinical outcomes.
Read more →TELATELA Bio Invests in Surgeon Training and Education with Upcoming Cadaver Lab
TELA Bio, Inc. is set to host a cadaver lab focused on advanced hernia repair techniques using its OviTex Reinforced Tissue Matrix on May 19 in Tampa, Florida. This initiative is part of a broader commitment to surgeon education, having conducted 98 medical programs in 2023 alone. The lab offers tailored educational experiences for surgeons of varying experience levels to enhance their skills in both open and robotic-assisted procedures. TELA Bio emphasizes its dedication to research and innovation in improving patient outcomes through effective surgical methods.
Read more →TELATELA Bio Reports First Quarter 2023 Financial Results MALVERN, PA
TELA Bio, Inc. reported a strong performance in Q1 2023, with revenue rising 45% year-over-year to $11.9 million. The company noted improvements in gross margins, attributing this to enhanced inventory management. However, TELA Bio also faced an increased net loss of $12 million in the same period, up from $10.9 million year-over-year. Despite macroeconomic challenges, the company remains optimistic about continued revenue growth and penetration in the market for the rest of the year.
Read more →TELATELA Bio Supports Diversity and Inclusion at International Hernia Collaboration Conference
TELA Bio, Inc. is sponsoring a Women in Surgery Dinner at the International Hernia Collaboration Conference in Rio de Janeiro, Brazil, to support female surgeons and promote gender equity in surgery. This event fosters networking and empowerment among women at all stages of their surgical careers. The initiative is part of TELA Bio's broader commitment to embracing diverse perspectives to drive progress in the medical field.
Read more →TELATELA Bio to Participate in the JMP Securities Life Sciences Conference
TELA Bio, Inc. announced its participation in the JMP Securities Life Sciences Conference scheduled for May 15th, 2023. The company will present its innovative soft-tissue reconstruction solutions that emphasize patient anatomy preservation. Interested parties can access the webcast of the presentation through TELA's investor relations website. This event underlines TELA Bio's commitment to advancing medical technology in the field.
Read more →TELATELA Bio to Announce First Quarter 2023 Financial Results
TELA Bio, Inc. announced that it will report its first quarter financial results for 2023 on May 11, 2023. The announcement includes details about a conference call and webcast scheduled for the same day at 4:30 p.m. ET to discuss the results. TELA Bio is a commercial-stage medical technology company that aims to provide innovative solutions for soft-tissue reconstruction, focusing on optimizing clinical outcomes by leveraging the patient's natural healing process.
Read more →TELA▼ -13.2%on this news
TELA Bio Announces Pricing of Public Offering of Common Stock
TELA Bio, Inc. has announced the pricing of a public offering of 4,750,000 shares of its common stock at $9.50 per share, aiming to raise approximately $45.125 million. The company has granted underwriters a 30-day option for an additional purchase of shares. Proceeds will be utilized for general corporate purposes, including sales, marketing, and R&D activities. The offering is expected to close around April 21, 2023, pending customary closing conditions. This follows a shelf registration statement declared effective by the SEC in December 2020.
Read more →TELATELA Bio Announces Proposed Public Offering of Common Stock
TELA Bio, Inc. has announced an underwritten public offering of its common stock aimed at enhancing its capital base. The proposed offering includes a 30-day option for underwriters to purchase additional shares. The net proceeds from this offering are intended for various corporate purposes, such as sales and marketing efforts and R&D activities. However, the completion of the offering is contingent on market conditions, and there can be no guarantee regarding its timing or size.
Read more →TELATELA Bio’s OviTex Reinforced Tissue Matrix to be Featured in Three Case Reports at SAGES 2023
TELA Bio, Inc. announced that its OviTex Reinforced Tissue Matrix will be highlighted in three case reports at the SAGES conference from March 29 to April 1, 2023, in Montreal, Canada. The presentations will provide insights into the use of OviTex in robot-assisted hernia repair, showcasing its unique design and compatibility with minimally invasive procedures. TELA Bio emphasizes the importance of its product in enhancing surgical outcomes while reducing reliance on permanent synthetic mesh. The company plans to engage with attendees at their booth during the event.
Read more →TELATELA Bio Announces 510(k) Clearance for OviTex PRS Long-Term Resorbable for Plastic and Reconstructive Surgery Company continues design advancements of biologic-based materials for soft tissue repair and reinforcement MA
TELA Bio, Inc. has received FDA 510(k) clearance for its OviTex PRS Long-Term Resorbable product, which is intended for use in soft tissue repair for plastic and reconstructive surgeries. This product adds to their existing OviTex PRS portfolio and features design enhancements that support functional tissue remodeling. The announcement was made by TELA's CEO, who emphasized the importance of such innovations in addressing the needs of surgeons and patients. However, the company did caution about potential risks that might impact its future performance.
Read more →TELATELA Bio Reports Fourth Quarter and Full Year 2022 Financial Results MALVERN, PA
TELA Bio, Inc. reported financial results for Q4 and the full year 2022, highlighting a 41% revenue growth despite facing macroeconomic challenges. In Q4, the company generated $11.6 million, an increase of 39% year-over-year, attributed to stronger international sales and the expansion of its commercial team. However, operating losses grew, reflecting increased expenses associated with its operational expansion. The company anticipates further revenue growth in 2023, projecting revenues between $60 million and $65 million.
Read more →TELA▲ +5.7%on this newsshared move
TELA Bio Highlights Published Clinical Research from 2022 Showcasing Safety and Performance of Reinforced Biologic for Hernia Indications
TELA Bio, Inc. has highlighted six studies from 2022 that showcase the safety and performance of their product, OviTex Reinforced Tissue Matrix, for hernia repairs. These studies indicate OviTex offers better outcomes than traditional synthetic and biologic mesh products, including lower complication and recurrence rates. Given the significant number of hernia repairs performed annually, the findings support OviTex's use as a preferred alternative. The research is part of TELA's commitment to optimizing clinical outcomes by enhancing soft-tissue reconstruction techniques.
Read more →TELATELA Bio to Announce Fourth Quarter and Full Year 2022 Financial Results
TELA Bio, Inc. has announced that it will report its fourth quarter and full year 2022 financial results on March 21, 2023. The company focuses on innovative technologies for soft-tissue reconstruction aimed at optimizing clinical outcomes. A conference call and webcast are scheduled for the same day to discuss these results and provide an update on corporate activities. Interested investors can register online to participate in the call.
Read more →TELATELA Bio Announces U.S. Commercial Launch of Two New OviTex LPR Device Configurations to Repair Large Abdominal Hernias Using Robotic and Laparoscopic Techniques Company continues to expand innovative product portfolio t
TELA Bio has announced the U.S. commercial launch of two new configurations for its OviTex LPR device aimed at repairing large abdominal hernias using robotic and laparoscopic techniques. The new sizes, 15 x 20 cm and 15 x 25 cm, will facilitate broader utilization among surgeons who favor minimally invasive procedures. OviTex LPR has been designed to provide long-term reinforcement and integrates a unique ovine-derived tissue matrix, enhancing functional tissue remodeling. The company aims to continue its expansion in the market to meet surgeon needs with innovative product offerings.
Read more →TELATELA Bio Awarded Biosynthetic Mesh Products Agreement with a National Group Purchasing Organization
TELA Bio, Inc. has announced a three-year dual-source agreement with a national group purchasing organization, which will provide its members with access to cost-effective biosynthetic products. This deal, effective until January 1, 2026, aims to expand the reach of TELA's OviTex Reinforced Tissue Matrix, designed for various surgical applications. The agreement is anticipated to facilitate growth opportunities and enhance clinical outcomes through advanced soft tissue reconstruction technologies. CEO Antony Koblish expressed excitement about the collaboration and its potential to meet the needs of clinicians and patients.
Read more →TELA▼ -9.3%on this news
INVESTOR PRESENTATION January 2023 Forward Looking Statements This presentation contains forward - looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 . All statements other than
TELA Bio, Inc. presented its forward-looking statements outlining future business strategies and potential market opportunities, specifically highlighting a $2.2 billion market opportunity for its advanced tissue matrix products. The company aims to enhance its commercial adoption through targeted sales approaches, with recent product launches in robotic hernia and reconstructive surgery markets. However, TELA acknowledges various risks and uncertainties that may affect its operations, including ongoing impacts from the COVID-19 pandemic and challenges in achieving market acceptance. These factors emphasize the dynamic nature of the healthcare industry and the uncertainties involved in future performance.
Read more →TELATELA Bio Announces U.S. Commercial Launch of NIVIS TM Fibrillar Collagen Pack, The Natural Restoration Solution to Support Healing of Surgical Wounds Company grows product portfolio, expanding product offerings to optimi
TELA Bio has announced the U.S. commercial launch of its NIVIS Fibrillar Collagen Pack, aimed at managing surgical wounds effectively. This product is designed with Type I and Type III bovine collagen to support healing and minimize complications, particularly in high-risk patients. TELA Bio's partnership with Collagen Matrix, Inc. expands its offerings in soft tissue preservation. While the product has significant benefits, there are warnings regarding allergic reactions in sensitive patients.
Read more →TELATELA Bio to Participate in the 41st Annual J.P. Morgan Healthcare Conference
MALVERN, Pa., Dec. 21, 2022 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the pati
Read more →TELATELA Bio to Participate in Piper Sandler 34th Annual Healthcare Conference
MALVERN, Pa., Nov. 21, 2022 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the pati
Read more →TELA▼ -8.7%on this news
TELA Bio Reports Third Quarter 2022 Financial Results MALVERN, PA
Third Quarter 2022 Financial Results MALVERN, PA, November 9, 2022 -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservatio
Read more →TELA▼ -7.2%on this news
TELA Bio to Participate in Canaccord MedTech, Diagnostics and Digital Health & Services Forum
MALVERN, Pa., Nov. 03, 2022 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the pati
Read more →TELATELA Bio to Announce Third Quarter 2022 Financial Results
MALVERN, Pa., Oct. 27, 2022 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the pati
Read more →TELATELA Bio Announces Publication of 24-Month BRAVO Study Results Demonstrating Benefits of OviTex Reinforced Tissue Matrix in Hernia Repair Study results show a low 2.6% recurrence rate and clinically meaningful improvemen
Publication of 24-Month BRAVO Study Results Demonstrating Benefits of OviTex Reinforced Tissue Matrix in Hernia Repair a low 2.6% recurrence rate and clinically meaningful improvement in patient quality of life MALVERN, PA, October 26, 2022 - TELA Bio, Inc. (NASDAQ: TELA), a c
Read more →TELATELA Bio to Participate in Upcoming Investor Conferences
MALVERN, Pa., Sept. 01, 2022 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the pat
Read more →TELATELA Bio to Participate in Inaugural Gilmartin Group Emerging Growth Company Showcase
MALVERN, Pa., Aug. 23, 2022 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the pati
Read more →TELATELA Bio Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriter’s Option to Purchase Additional Shares
MALVERN, Pa., Aug. 18, 2022 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the pati
Read more →TELAINVESTOR PRESENTATION August 2022 Forward Looking Statements This presentation contains forward - looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 . All statements other than
INVESTOR PRESENTATION August 2022 Forward Looking Statements This presentation contains forward - looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 . All statements other than statements of historical facts contained in this document,
Read more →TELATELA Bio Reports Second Quarter 2022 Financial Results MALVERN, PA
TELA Bio Reports Second Quarter 2022 Financial MALVERN, PA, August 10, 2022 -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the pr
Read more →TELATELA Bio Highlights Results from BRAVO and ReBAR Studies on the Benefits of OviTex Reinforced Tissue Matrix in Hernia Repairs; Data to Be Presented at 2022 American Hernia Society (AHS) Meeting
24-Month BRAVO study results showed a 2.6% recurrence rate in diverse clinical scenarios Robotic Reinforced Biologic Augmented Repair (ReBAR) study showed a 1.9% recurrence rate at two-year mark MALVERN, Pa., Aug. 04, 2022 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ: TELA), a co
Read more →TELATELA Bio to Announce Second Quarter 2022 Financial Results
MALVERN, Pa., July 27, 2022 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the pati
Read more →TELATELA Bio Awarded Synthetic Bioabsorbable Mesh Products Agreement with Premier, Inc.
MALVERN, Pa., July 20, 2022 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the pati
Read more →TELATELA Bio to Participate in Upcoming JMP Securities Life Sciences Conference
MALVERN, Pa., June 02, 2022 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the pati
Read more →TELA▼ -5%on this news· ran to -15% by day 3shared move
TELA Bio Secures Up to $50 Million in Debt Financing from MidCap Financial
MALVERN, Pa., May 31, 2022 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restorati
Read more →TELA▲ +6.2%on this newsshared move
TELA Bio to Participate in Upcoming Jefferies Healthcare Conference
MALVERN, Pa., May 26, 2022 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patie
Read more →TELATELA Bio Reports First Quarter 2022 Financial Results MALVERN, PA
First Quarter 2022 Financial Results PA, May 10, 2022 -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration
Read more →TELATELA Bio to Participate in Upcoming 2022 H.C. Wainwright Annual Global Investment Conference
MALVERN, Pa., May 09, 2022 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patie
Read more →TELATELA Bio to Announce First Quarter 2022 Financial Results
MALVERN, Pa., April 26, 2022 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the pat
Read more →TELA▼ -5%on this news
TELA Bio Appoints D. Taylor Ocasio as General Counsel
MALVERN, Pa., April 18, 2022 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the pat
Read more →TELATELA Bio to Participate in Upcoming Needham & Co. 21st Annual Healthcare Virtual Conference
MALVERN, Pa., March 30, 2022 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the pat
Read more →TELATELA Bio Reports Fourth Quarter and Full Year 2021 Financial Results MALVERN, PA
Fourth Quarter and Full Year 2021 Financial Results MALVERN, PA, March 21, 2022 -- TELA Bio, Inc. ("TELA") (Nasdaq: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prio
Read more →TELATELA Bio to Participate in Upcoming Canaccord Genuity Musculoskeletal Conference in Chicago, IL
MALVERN, Pa., March 16, 2022 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the pat
Read more →TELATELA Bio to Announce Fourth Quarter and Full Year 2021 Financial Results
MALVERN, Pa., March 07, 2022 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restora
Read more →TELATELA Bio Announces U.S. Commercial Launch of SiteGuard TM No Rinse Antimicrobial Solution Company expands product portfolio with focus on addressing surgical site infections in plastic reconstructive surgery MALVERN, PA
TELA Bio Announces U.S. Commercial Launch of SiteGuardTM No Rinse Antimicrobial Solution Company expands product portfolio with focus on addressing surgical site infections in plastic reconstructive surgery MALVERN, PA March 3, 2022 - TELA Bio, Inc. (NASDAQ: TELA), a commerc
Read more →TELATELA Bio Reports Strong Third Quarter 2021 Revenues Reflecting Continued Growth Driven by Increased Demand MALVERN, Pa.
TELA Bio Reports Strong Third Quarter 2021 Revenues Reflecting Continued Growth Driven by Increased Demand MALVERN, Pa., November 10, 2021 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA") (Nasdaq: TELA), a commercial-stage medical technology company focused on designing, developing
Read more →TELATELA Bio Announces Publication of 12-Month Results from the BRAVO Study with Continued Positive Outcomes Through 24 months 12-month follow-up data in 75 patients treated with OviTex Reinforced Tissue Matrix (RTM) for ven
TELA Bio Announces Publication of 12-Month Results from the BRAVO Study with Continued Positive Outcomes Through 24 months MALVERN, PA November 9th, 2021 - TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on designing, developing, and marke
Read more →TELATELA Bio to Participate in Three Upcoming Conferences
MALVERN, Pa., Nov. 08, 2021 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on designing, developing, and marketing innovative tissue reinforcement materials to address unmet needs in soft tissue reconstruction, today announced t
Read more →TELATELA Bio and Next Science Enter into Exclusive Distribution Agreement in the Plastic Reconstructive Market for Advanced Anti-Biofilm Surgical Wash Agreement includes exclusive right to sell and market Next Science's prop
TELA Bio and Next Science Enter into Exclusive Distribution Agreement in the Plastic Reconstructive Market for Advanced Anti-Biofilm Surgical Wash Agreement includes exclusive right to sell and market Next Science's proprietary no rinse antimicrobial solution in the US and f
Read more →TELATELA Bio to Announce Third Quarter 2021 Financial Results
MALVERN, Pa., Oct. 27, 2021 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on designing, developing, and marketing innovative tissue reinforcement materials to address unmet needs in soft tissue reconstruction, today announced t
Read more →TELATELA Bio Appoints Roberto Cuca as Chief Operating Officer and Chief Financial Officer
MALVERN, Pa., Sept. 27, 2021 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on designing, developing, and marketing innovative tissue reinforcement materials to address unmet needs in soft tissue reconstruction, today announced
Read more →TELATELA Bio Announces New Data on Use of OviTex in a Range of Hernia Repair Applications, Including Novel ReBAR (Reinforced Biologic Augmented Repair) Technique
MALVERN, Pa., Sept. 13, 2021 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on designing, developing, and marketing innovative tissue reinforcement materials to address unmet needs in soft tissue reconstruction, today anno
Read more →TELATELA Bio's OviTex Reinforced Tissue Matrix to be Featured in Three Presentations at SAGES 2021
MALVERN, Pa., Aug. 16, 2021 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on designing, developing, and marketing innovative tissue reinforcement materials to address unmet needs in soft tissue reconstruction, today annou
Read more →TELATELA Bio Reports Record Second Quarter 2021 Revenues Driven by Increased Demand MALVERN, Pa.
TELA Bio Reports Record Second Quarter 2021 Revenues Driven by Increased Demand Pa., August 11, 2021 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA") (Nasdaq: TELA), a commercial-stage medical technology company focused on designing, developing, and marketing innovative tissue rein
Read more →TELATELA Bio to Participate in Canaccord Genuity’s 41st Annual Growth Conference
MALVERN, Pa., Aug. 03, 2021 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on designing, developing, and marketing innovative tissue reinforcement materials to address unmet needs in soft tissue reconstruction, today announced t
Read more →TELATELA Bio to Announce Second Quarter 2021 Financial Results
MALVERN, Pa., July 28, 2021 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on designing, developing, and marketing innovative tissue reinforcement materials to address unmet needs in soft tissue reconstruction, today announced t
Read more →TELATELA Bio Announces Changes to its Board of Directors
MALVERN, Pa., June 02, 2021 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on designing, developing, and marketing innovative tissue reinforcement materials to address unmet needs in soft tissue reconstruction, today announced t
Read more →TELATELA Bio Names Marissa Conrad as Vice President of Clinical and Regulatory Affairs
MALVERN, Pa., May 25, 2021 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on designing, developing, and marketing innovative tissue reinforcement materials to address unmet needs in soft tissue reconstruction, announced the appo
Read more →TELATELA Bio Initiates BRAVO II Study of OviTex for the Robotic Repair of Ventral Hernias MALVERN, PA
Bio Initiates BRAVO II Study of OviTex for the Robotic Repair of Ventral Hernias MALVERN, PA, May 19, 2021 -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on designing, developing, and marketing innovative tissue reinforcement materials to addr
Read more →TELATELA Bio Announces First Quarter 2021 Financial Results MALVERN, Pa.
First Quarter 2021 Financial Results MALVERN, Pa., May 13, 2021 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA") (Nasdaq: TELA), a commercial stage medical technology company focused on designing, developing, and marketing innovative tissue reinforcement materials to address unmet
Read more →TELATELA Bio to Announce First Quarter 2021 Financial Results
MALVERN, Pa., April 29, 2021 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on designing, developing, and marketing innovative tissue reinforcement materials to address unmet needs in soft tissue reconstruction, today announced
Read more →TELAAdvancing Soft Tissue Reconstruction Investor Presentation January 2021 2 Forward Looking Statements This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Ac
We will report fourth quarter and full year 2020 financial results in March 2021. Our actual results may differ from these preliminary results and such differences may be material. 20 Investment Highlights Advanced reinforced tissue matrix portfolio supported by compelling clinic
Read more →TELATELA Bio Announces Fourth Quarter and Full Year 2020 Financial Results MALVERN, Pa.
TELA Bio Announces Fourth Quarter and Full Year 2020 Financial Results MALVERN, Pa., March 24, 2021 -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on designing, developing, and marketing innovative tissue reinforcement materials to address u
Read more →TELATELA Bio Announces 12-Month Analysis from BRAVO Study of OviTex for Ventral Hernia Repair
MALVERN, Pa., March 18, 2021 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on designing, developing, and marketing innovative tissue reinforcement materials to address unmet needs in soft tissue reconstruction, today announced
Read more →TELATELA Bio to Report Fourth Quarter and Full Year 2020 Financial Results on March 24, 2021
MALVERN, Pa., March 02, 2021 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on designing, developing, and marketing innovative tissue reinforcement materials to address unmet needs in soft tissue reconstruction, today announced
Read more →TELATELA Bio to Participate in Upcoming BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
MALVERN, Pa., Feb. 04, 2021 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on designing, developing, and marketing innovative tissue reinforcement materials to address unmet needs in soft tissue reconstruction, today announced t
Read more →TELATELA Bio Reports Preliminary Results for Fourth Quarter and Full Year 2020 MALVERN, Pa.
Bio Reports Preliminary Results for Fourth Quarter and Full Year 2020 Pa., January 14, 2021 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA") (Nasdaq: TELA), a commercial-stage medical technology company focused on designing, developing and marketing a new category of tissue reinforc
Read more →TELATELA Bio to Participate in Upcoming Needham Virtual Growth Conference
MALVERN, Pa., Jan. 06, 2021 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on designing, developing and marketing a new category of tissue reinforcement materials to address unmet needs in soft tissue reconstruction, today annou
Read more →TELATELA Bio Appoints Renowned Surgeon as Vice President of Clinical Development
Bruce Freedman, M.D. joins innovative MedTech company to advocate for more natural surgical hernia mesh options MALVERN, Pa., Jan. 05, 2021 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA") (Nasdaq: TELA), an innovative MedTech company focused on advancing the field of soft-tissue rec
Read more →TELATELA Bio to Participate in Upcoming Piper Sandler 32nd Annual Virtual Healthcare Conference
MALVERN, Pa., Nov. 24, 2020 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on designing, developing and marketing a new category of tissue reinforcement materials to address unmet needs in soft tissue reconstruction, today annou
Read more →TELAAdvancing Soft Tissue Reconstruction Investor Presentation November 2020 2 Forward Looking Statements This presentation contains forward - looking statements within the meaning of The Private Securities Litigation Reform
Advancing Soft Tissue Reconstruction Investor Presentation November 2020 2 Forward Looking Statements This presentation contains forward - looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 . All statements other than statements of hist
Read more →TELATELA Bio Announces Third Quarter 2020 Financial Results MALVERN, Pa.
TELA Bio Announces Third Quarter 2020 MALVERN, Pa., November 11, 2020 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA") (Nasdaq: TELA), a commercial-stage medical technology company focused on designing, developing and marketing a new category of tissue reinforcement materials to ad
Read more →TELATELA Bio to Participate at Upcoming Investor Conferences
MALVERN, Pa., Nov. 10, 2020 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on designing, developing and marketing a new category of tissue reinforcement materials to address unmet needs in soft tissue reconstruction, announced t
Read more →TELATELA Bio to Announce Third Quarter 2020 Financial Results and Host Conference Call on November 11, 2020
MALVERN, Pa., Oct. 21, 2020 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (Nasdaq: TELA), a commercial stage medical technology company focused on designing, developing and marketing a new category of tissue reinforcement materials to address unmet needs in soft tissue reconstr
Read more →TELATELA Bio Presents Additional Data from BRAVO Study of OviTex for Ventral Hernia Repair MALVERN, PA
Additional Data from BRAVO Study of OviTex Ventral Hernia Repair MALVERN, PA, September 25, 2020 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on designing, developing and marketing a new category of tissue reinforcement ma
Read more →TELATELA Bio to Participate at Upcoming Conferences
MALVERN, Pa., Sept. 02, 2020 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on designing, developing and marketing a new category of tissue reinforcement materials to address unmet needs in soft tissue reconstruction, announced
Read more →TELATELA Bio Announces Second Quarter 2020 Financial Results MALVERN, Pa.
TELA Bio Announces Second Quarter 2020 MALVERN, Pa., August 12, 2020 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA") (Nasdaq: TELA), a commercial stage medical technology company focused on designing, developing and marketing a new category of tissue reinforcement materials to add
Read more →TELATELA Bio to Participate at the Canaccord Genuity 40th Annual Growth Conference
MALVERN, Pa., July 30, 2020 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA") (Nasdaq: TELA), a commercial-stage medical technology company focused on designing, developing and marketing a new category of tissue reinforcement materials to address unmet needs in soft tissue reconstructi
Read more →TELATELA Bio to Announce Second Quarter 2020 Financial Results and Host Conference Call on August 12, 2020
MALVERN, Pa., July 23, 2020 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (Nasdaq: TELA), a commercial stage medical technology company focused on designing, developing and marketing a new category of tissue reinforcement materials to address unmet needs in soft tissue reconstr
Read more →TELATELA Bio Announces Interim Analysis from BRAVO Study of OviTex for Ventral Hernia Repair MALVERN, Pa.
Bio Announces Interim Analysis from BRAVO Study of OviTex for Ventral MALVERN, Pa., July 9, 2020 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on designing, developing and marketing a new category of tissue reinforcement mat
Read more →TELATELA Bio Announces Closing of Public Offering of Common Stock
MALVERN, Pa., June 30, 2020 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA”), a commercial-stage medical technology company focused on designing, developing and marketing a new category of tissue reinforcement materials to address unmet needs in soft tissue reconstruction, today annou
Read more →TELATELA Bio, Inc. to Join the Russell 2000 Index
MALVERN, Pa., June 22, 2020 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA") (Nasdaq: TELA), a commercial stage medical technology company focused on designing, developing and marketing a new category of tissue reinforcement materials to address unmet needs in soft tissue reconstructi
Read more →TELATELA Bio, Inc. Announces Poster Presentations at the 2020 Minimally Invasive Surgery Symposium (MISS) MALVERN, Pa.
TELA Bio, Inc. Announces Poster Presentations at the 2020 Minimally Invasive Surgery Symposium (MISS) MALVERN, Pa., June 15, 2020 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA") (Nasdaq: TELA), a commercial stage medical technology company focused on designing, developing and mar
Read more →TELATELA Bio to Present at the Jefferies Virtual Healthcare Conference
MALVERN, Pa., May 29, 2020 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA") (Nasdaq: TELA), a commercial stage medical technology company focused on designing, developing and marketing a new category of tissue reinforcement materials to address unmet needs in soft tissue reconstructio
Read more →TELATELA Bio: Advancing Soft Tissue Reconstruction May 2020 2 Forward Looking Statements This presentation contains forward - looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 . Al
1 TELA Bio: Advancing Soft Tissue Reconstruction May 2020 2 Forward Looking Statements This presentation contains forward - looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 . All statements other than statements of historical facts co
Read more →TELATELA Bio Announces First Quarter 2020 Financial Results MALVERN, Pa.
TELA Bio Announces First Quarter 2020 MALVERN, Pa., May 12, 2020 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA") (Nasdaq: TELA), a commercial stage medical technology company focused on designing, developing and marketing a new category of tissue reinforcement materials to address
Read more →TELATELA Bio to Announce First Quarter 2020 Financial Results and Host Conference Call on May 12, 2020
MALVERN, Pa., April 28, 2020 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (Nasdaq: TELA), a commercial stage medical technology company focused on designing, developing and marketing a new category of tissue reinforcement materials to address unmet needs in soft tissue reconst
Read more →TELATELA Bio Announces Changes to its Board of Directors MALVERN, Pa.
TELA Bio Announces Changes to its Board MALVERN, Pa., April 23, 2020 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (Nasdaq: TELA), a commercial stage medical technology company focused on designing, developing and marketing a new category of tissue reinforcement materials to
Read more →TELATELA Bio: Advancing Soft Tissue Reconstruction April 2020 2 Forward Looking Statements This presentation contains forward - looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 .
1 TELA Bio: Advancing Soft Tissue Reconstruction April 2020 2 Forward Looking Statements This presentation contains forward - looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 . All statements other than statements of historical facts
Read more →TELATELA Bio Announces Fourth Quarter and Full Year 2019 Financial Results MALVERN, Pa.
TELA Bio Announces Fourth Quarter and Full Year 2019 Financial Results MALVERN, Pa., March 27, 2020 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA") (Nasdaq: TELA), a commercial stage medical technology company focused on designing, developing and marketing a new category of tissu
Read more →TELATELA Bio to Announce Fourth Quarter and Full Year 2019 Financial Results and Host Conference Call on March 27, 2020
MALVERN, Pa., March 11, 2020 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA") (Nasdaq: TELA), a commercial stage medical technology company focused on designing, developing and marketing a new category of tissue reinforcement materials to address unmet needs in soft tissue reconstruct
Read more →TELATELA Bio Announces Publication of Results from In-Vivo Study Demonstrating Favorable Response to Reinforced Biologics in Hernia Repair
MALVERN, Pa., Feb. 04, 2020 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA”) (Nasdaq: TELA), a commercial stage medical technology company focused on designing, developing and marketing a new category of tissue reinforcement materials to address unmet needs in soft tissue reconstructi
Read more →TELATELA Bio Announces Appointment of New Chief Commercial Officer MALVERN, Pa.
TELA Bio Announces Appointment of New Chief Commercial Officer MALVERN, Pa., January 29, 2020 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA") (Nasdaq: TELA), a commercial stage medical technology company focused on designing, developing and marketing a new category of tissue reinf
Read more →TELATELA Bio Announces Preliminary Revenue for Fourth Quarter and Full Year 2019 - Preliminary fourth quarter 2019 revenue increased 94%-102% year-over-year to $4.7 million to $4.9 million - Preliminary full year 2019 revenu
TELA Bio Announces Preliminary Revenue for Fourth Quarter MALVERN, Pa., January 10, 2020 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA") (Nasdaq: TELA), a commercial stage medical technology company focused on designing, developing and marketing a new category of tissue reinforcem
Read more →TELATELA Bio Announces Third Quarter 2019 Financial Results - Revenue increased 80% year-over-year to $4.0 million - Completed initial public offering in November 2019, raising net proceeds of $50.7 million MALVERN, Pa.
TELA Bio Announces Third Quarter 2019 Financial Results MALVERN, Pa., December 18, 2019 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA") (Nasdaq: TELA), a commercial stage medical technology company focused on designing, developing and marketing a new category of tissue reinforceme
Read more →TELATELA Bio Awarded Contract with HealthTrust Purchasing Group MALVERN, Pa.
Bio Awarded Contract with HealthTrust Purchasing Group MALVERN, Pa., December 6, 2019 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA") (Nasdaq: TELA), a commercial stage medical technology company focused on designing, developing and marketing a new category of tissue reinforcement
Read more →TELATELA Bio Appoints Federica O’Brien to Board of Directors
MALVERN, Pa., Nov. 13, 2019 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA”) (Nasdaq: TELA), a commercial stage medical technology company focused on designing, developing and marketing a new category of tissue reinforcement materials to address unmet needs in soft tissue reconstructi
Read more →TELATELA Bio Announces Closing of Initial Public Offering of Common Stock
MALVERN, Pa., Nov. 13, 2019 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA”) (Nasdaq: TELA), a commercial stage medical technology company focused on designing, developing and marketing a new category of tissue reinforcement materials to address unmet needs in soft tissue reconstructi
Read more →TELATELA Bio Announces Pricing of Initial Public Offering of Common Stock
MALVERN, Pa., Nov. 07, 2019 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA”), a commercial stage medical technology company focused on designing, developing and marketing a new category of tissue reinforcement materials to address unmet needs in soft tissue reconstruction, today annou
Read more →Competitive Position
How TELA ranks across every disease it competes inCompetitive Position is a premium feature
See how TELA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial